"在ObesityWeek®展示我们强劲的小分子与多肽肥胖症管线的持续进展，我们倍感振奋，"歌礼创始 人、董事会主席兼首席执行官吴劲梓博士表示，"这些进展充分体现了我们开发高度差异化的肥胖症治 疗方案的坚定决心。" 歌礼制药-B(01672)发布公告，公司董事会宣布将在美国佐治亚州亚特兰大举行的2025年肥胖周 (ObesityWeek®)以壁报形式报告多款肥胖症候选药物，包括ASC30以及 ASC31与ASC47联合疗法。 ...

歌礼制药-B(01672)发布公告，公司董事会宣布将在美国佐治亚州亚特兰大举行的2025年肥胖周 (ObesityWeek)以壁报形式报告多款肥胖症候选药物，包括ASC30以及ASC31与ASC47联合疗法。 "在ObesityWeek展示我们强劲的小分子与多肽肥胖症管线的持续进展，我们倍感振奋，"歌礼创始人、 董事会主席兼首席执行官吴劲梓博士表示，"这些进展充分体现了我们开发高度差异化的肥胖症治疗方 案的坚定决心。" ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 Ascletis Pharma Inc. 歌禮製藥有限公司 歌禮將攜ASC30口服片、ASC30注射劑和ASC31與ASC47聯合療法的 研究結果亮相2025年肥胖周（ObesityWeek®） 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈將在美國佐治亞州亞特蘭大舉行的2025 年肥胖周（ObesityWeek®）以壁報形式報告多款肥胖症候選藥物，包括ASC30以及 ASC31與ASC47聯合療法。 報告細節： ASC30是一款正在臨床研究中的小分子GLP-1R偏向激動劑，具有獨特和差異化性 質，使得同一小分子同時適用於口服片劑和皮下注射給藥成為可能。ASC30是一 種新化學實體(NCE)，擁有 ...

Core Viewpoint - The announcement from the company reflects a strong commitment to its long-term value and future prospects, as demonstrated by the voluntary shareholding commitment from key executives [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and He Jingdao have voluntarily committed not to sell or pledge any shares they control until the release of three key clinical trial data points [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and his wife amounts to 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares) [1]

Core Viewpoint - The company expresses strong confidence in its long-term value and future prospects through a voluntary commitment by its founder and major shareholders to not sell any shares before the release of three key clinical trial data points [1] Group 1: Clinical Trial Data Commitments - The founder, Dr. Wu, and his spouse, Ms. He, have committed not to sell or pledge any shares they control until the following clinical data readouts: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with Semaglutide in obese subjects, expected by the end of September 2025 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected by the end of December 2025 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by the end of December 2025 [1][1][1] Group 2: Shareholding Information - As of the announcement date, Dr. Wu and Ms. He hold a total of 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares) [1][1][1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has announced a voluntary commitment by its founder and major shareholders to not sell any shares before the release of three key clinical trial data points, reflecting their confidence in the company's long-term value and future prospects [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and Ms. He Jingdao have committed to not selling or pledging any shares they control until the release of three specific clinical trial results [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide in obese subjects, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected by the end of December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by the end of December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and Ms. He is approximately 576 million shares, representing about 58.03% of the company's existing issued share capital (excluding treasury shares) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出。 本公司董事（「董事」）會（「董事會」）謹此宣布，其獲告知，為表達對本公司長遠 價值及未來前景的堅定信心，吳勁梓博士（歌禮創始人、董事會主席兼首席執行 官、及本公司控股股東，「吳博士」），與何淨島（本公司執行董事及控股股東、吳 博士之配偶，「吳夫人」）一起，已自願承諾在如下3個臨床數據讀出前，不會出 售（包括但不限於出售或質押）任何由彼等或彼等各自控制的實體直接或間接實益 擁有的本公司股份（「股份」）：(i) ASC47聯合司美格魯肽在肥胖受試者中進行的 美國I期臨床研究頂線數據，預計於2025年9月底獲得；(ii) ASC30口服片在肥胖 或超重受試者中進行的美國13周IIa期臨床研究頂線數據，預計於2025年12月獲 得；及(iii) ASC50在健康受試者中進行的美國I期單劑量遞增研究頂線數據，預 計於202 ...

Core Viewpoint - The company reported a significant increase in losses and a drastic decline in revenue, while highlighting advancements in its metabolic disease pipeline, particularly in obesity treatment [1][2] Financial Performance - The company reported a revenue of RMB 128.3 million, a decrease of 97.73% year-on-year [1] - Shareholder losses amounted to RMB 301 million, an increase of 107.95% compared to the previous year [1] - Earnings per share were reported at a loss of 30.05 cents [1] Research and Development Progress - The company made significant progress in its metabolic disease pipeline, particularly in obesity treatments: - ASC30 oral tablets showed potential as a best-in-class treatment, with an average weight loss of up to 6.3% relative to baseline after 28 days of treatment [1] - ASC30, a once-monthly or less frequent subcutaneous injection, is positioned as a first-in-class small molecule GLP-1R agonist for obesity treatment, with interim data expected by the end of March 2025 [1] - ASC47, another once-monthly or less frequent subcutaneous injection, is a novel small molecule thyroid hormone receptor β (THRβ) agonist aimed at weight loss without muscle loss, demonstrating a half-life of up to 40 days in obese patients [1] Strategic Outlook - The company emphasized its strong R&D capabilities and commitment to developing globally competitive differentiated pipeline products [2] - The increase in losses was primarily attributed to rising R&D expenses for obesity and other metabolic diseases [2] - The company has sufficient funding to support its innovative R&D efforts over the next five years [2]